CAR T-cell therapy in LMICs: approval of talicabtagene autoleucel in India.

COI Statement

MR reports grants and personal fees from viTToria Bio; non-financial support from Beckman Coulter and ORFLO; personal fees from GSK, Bristol Myers Squibb, Sana, NanoString, GLG, and Guidepoint; grants from AbClon and ONI; and multiple patents on CAR T immunotherapy managed by the University of Pennsylvania that are pending, issued, licensed, and with royalties paid from viTToria Bio, Novartis, and Tmunity. LP declares no competing interests.